摘要
Background: Selpercatinib, a highly selective and potent REarranged during Transfection (RET) kinase inhibitor, is effective in advanced RET-altered thyroid cancer (TC). However, the efficacy and safety in Chinese patients are unknown. Patients and methods: In the open-label, multi-center phase II LIBRETTO-321 (NCT04280081) study, Chinese patients with advanced solid tumors harboring RET alterations received selpercatinib 160 mg twice daily. The primary endpoint was objective response rate (ORR; RECIST v1.1) by independent review committee (IRC). Secondary endpoints included duration of response (DoR) and safety. Efficacy was assessed in the primary analysis set [PAS; treated patients with RET fusion-positive TC or RET-mutant medullary TC (MTC) confirmed by central laboratory] and all enrolled patients with MTC. Results: Of 77 enrolled patients, 29 had RET-mutant MTC and one had RET fusion-positive TC. In the PAS (n = 26), the ORR by IRC was 57.7% [95% confidence interval (CI), 36.9-76.6]. Median DoR was not reached and 93.3% of responses were ongoing at a median follow-up of 8.7 months. In all enrolled MTC patients (n = 29), the ORR by IRC was 58.6% (95% CI, 38.9-76.5). One RET fusion-positive TC patient treated for 23.4 weeks achieved a partial response at week 8 that was ongoing at cutoff. In the safety population (n = 77), 59.7% experienced grade > 3 treatment-emergent adverse events (TEAEs). TEAEs led to dose reductions in 32.5% (n = 25) and discontinuations in 5.2% [n = 4; 3.9% (n = 3) considered treatment related] of patients. Conclusions: Selpercatinib showed robust antitumor activity and was well tolerated in Chinese patients with advanced RET-altered TC, consistent with global data from LIBRETTO-001 (NCT04280081). ClinicalTrials.gov Identifier: NCT04280081 (first posted Feb 21, 2020)
学科与关键词
- LIBRETTO-321, a phase II study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)Zheng, X.; Ji, Q.; Sun, Y.; Ge, M.; Zhang, B.; Cheng, Y.; Lei, S.; Shi, F.; Zhang, W.; Gao, M.ESMO Targeted Anticancer Therapies Congress (TAT), ELECTR NETWORK, 2022-03-07 To 2022-03-08.被引 1
- A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumorsZhou, Qing; Wu, Yi-Long; Zheng, Xiangqian; Li, Dapeng; Huang, Dingzhi; Li, Xingya; Liu, Anwen; Song, Xia; Jing, Shanghua; Wang, Mingxia; Wang, Xicheng; Luo, Yongzhong; Song, Yong; Mi, Yanjun; Zhou, Jianying; Fan, Yun; Su, Haichuan; Huang, Tao; Ouyang, Weiwei; Ge, JunyouAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
- Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 studyZhao, Jingzhu; Chi, Yihebali; Hu, Chuanxiang; Chen, Xiaohong; Ge, Minghua; Zhang, Yuan; Guo, Zhuming; Wang, Jun; Chen, Jie; Zhang, Jiewu; Cheng, Ying; Li, Zhendong; Liu, Hui; Qin, Jianwu; Zhu, Jingqiang; Cheng, Ruochuan; Xu, Zhengang; Li, Dapeng; Tang, Pingzhang; Gao, Ming*; Zheng, Xiangqian*Frontiers in Oncology, 2022, 12: 852032.被引 2
